Evonik
Tuesday, November 17, 2020
10:00 a.m. EST / 4:00 p.m. CET

Delayed release formulations: The latest innovations for enteric coatings, delivery technologies and continuous manufacturing

Back to overview

Overview

The use of enteric coatings is becoming an increasingly popular method by which pharmaceutical and biopharma companies can increase the functional performance and processability of their drug products in an oral solid dosage form.

In this webinar, speakers will review how to increase the flexibility of functional coatings or enable rapid, precise release in particular GIT regions such as the upper small intestine. Specific functionality challenges and solutions for dosage forms including Multiple-Unit-Particulate-Systems (MUPS) and softgels will be reviewed.

Other case studies will explore how to further reduce processing time and cost for delayed release formulations, as well as new developments in continuous manufacturing.

Experts featuring this session

Felix Hofmann
Technical Sales Manager
Vita
Felix Hofmann is currently Manager Technical Sales at the Formulation Application Services EMEA at Evonik Nutrition & Care GmbH, Darmstadt, Germany. His responsibility is a holistic technical support for key and strategic accounts.

From 2002 to 2005 he made an education as chemical laboratory
technician at Röhm GmbH & Co.KG, Darmstadt, Germany including theory and practice in polymerization and application technology.

In 2015 Felix completed his degree as a process engineer specialized in pharmaceutical technology at the university of applied science FH Bingen, Germany. The topic of his B.Sc. thesis was “Fluidized bed technology as an alternative to conventional spray drying technology for bioavailability enhancement of celecoxib by adsorption on solid carriers”.

Felix started his career in 2005 at the technical service laboratory for EUDRAGIT®® polymers. From 2006 to 2008 worked as a Scientist and from 2008 to 2012 as a Senior Scientist looking after customer requests, customer projects and process troubleshooting during scale up and production of coated particles or tablets for northern Europe.

From 2012 to 2015 he worked as a Principal Scientist with focus on complex customer projects including GMP and HPAPI requirements. Until 2017 he was responsible for evaluation, design and implementation of customer projects for pharmaceutical and nutraceutical oral dosage forms as Technical Project Coordinator.

He has published several papers and posters on the application of pharmaceutical methacrylates in the formulation of solid dosage forms and is co - inventor of several patents.
Dr. Jessica Müller-Albers
Strategic Marketing Director
Vita
Dr. Jessica Müller-Albers joined Evonik’s Health Care business line in 2010 and is currently working as Strategic Marketing Director for oral solutions.

Before taking over the current position she was group leader for drug delivery where she focused on the development and analytics of new oral and parenteral platform technologies for the pharma and food industry as well as the development of cell culture media.

She held different positions in application service and formulation development of oral excipients and worked for a contract manufacturer where she gained experience in developing solid and semi-solid dosage forms, product transfer, manufacturing of clinical-trial medication, GMP and high potent handling.

She received her degree in pharmacy from the University of Halle/Saale and her Ph.D. from the University of Duesseldorf where she specialized on melt extrusion of poorly soluble drugs.

Moreover, she authored several research papers, book chapters and patents.

Register now

Details

Webinar language:
English

Venue

Online

Questions?

Stephen Allan
External Communications
+49 6151 18 3508 E-Mail
Register now
Evonik Health Care
Company Information
Legal Notice
Privacy Policy